Attorney Docket Number	4239-66190-01
Application Number	10/607,598
Filing Date	June 27, 2003
First Named Inventor	Martin
Art Unit	1646 1647
Examiner Name	Jegatheesan Seharaseyon

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

IAP66 JAN 24 2007 PATENT & TRADEMARK OFFICE

Examiner's Initials	Cite No. (optional)	OTHER DOCUMENTS
/JS/		Bielekova et al., "Daclizumab Inhibits Inflammation and Stabilizes Disease Progression in MS," *Short Communication - Annals of Neurology*, 17 pages, August 14, 2006
/JS/		Bielekova et al., "Humanized anti-CD25 (daclizumab) inihibits disease activity in multiple sclerosis patients failing to respond to interferon {beta}," *PNAS* 101(23):8705-8708 (June 8, 2004)
/JS/		Bielekova et al., "Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R {alpha}-targeted therapy (daclizumab) in multiple sclerosis," *PNAS* 103(15):5941-5946 (April 11, 2006)
/JS/		Rose et al., "Treatment of Multiple Sclerosis with an Anti-Interleukin-2 Receptor Monoclonal Antibody," *Ann Neurol* 56:864-867 (2004)

EXAMINER SIGNATURE:	/Jegatheesan Seharaseyon/	DATE CONSIDERED:	04/13/2007

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.